Dr. Jatin Kothari

Dr. Jatin Kothari
Nephrologist, Mumbai

DM (Nephrology), M.D. (Medicine), M.B.B.S.

  • 1 Hospital
  • Consultant Nephrologist and Transplant Physician 
    with P. D. Hinduja National Hospital and Research Center, Mahim, Mumbai

Specialities

  • Nephrology

  • Transplant surgery

Expertise

Education

  • DM(Nephrology) from Bombay University
  • MD(Medicine) from Bombay University
  • MBBS from Bombay University
  • Fellow,International Society of Nephrology
  • International Transplant Observership, Massachusetts General Hospital, Boston, USA,2009
  • Roche Preceptorship in Kidney Transplantation,University of Alabama,Birmingham, USA ,2006

Practice Information

P.D. Hinduja National Hospital & Research Center, Mumbai

P.D. Hinduja National Hospital & Research Center, Mumbai

Veer Savarkar Marg, Mahim, Mumbai, Maharashtra - 400016

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Jatin Kothari and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Study effects of glycemic control on outcomes in peritoneal dialysis(Toronto peritoneal dialysis registry)
  • Intraperitoneal v/s subcutaneous insulin regimes in peritoneal dialysis (Toronto peritoneal dialysis registry)
  • Lipid control in peritoneal dialysis patients-are we meeting targets? (Toronto peritoneal dialysis registry)
  • study of gaps in metabolic acidosis to unmask metabolic alkalosis
  • prospective study of renal disease in Sjogren’s syndrome
  • comparison of creatinine clearance and serum cystatin as markers for estimation of renal function-study completed
  • clinical outcomes in lupus nephritis(data collection completed)
  • An evaluation of safety and efficacy of rHu Epo in treatment of anemia in patients with chronic kidney disease-A prospective open labeled multicenter study-coinvestigator(completed)
  • A randomized single blinded active drug comparitive parallel group, mulitcenter, multinational therapeutic confirmatory study to evaluate safety and efficacy of aropotin v/s espogen in chronic kidney disease patients-co investigator(completed)
  • A Randomized, Double-Blind, Placebo-Controlled, Four Arm, Parallel-Group, Multicenter, Multinational, Safety And Efficacy Trial of 100 mg, 300 mg and 900 mg of Abetimus Sodium In Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease”-Principal investigator-study completed
  • Belatacept Evaluation of Nephroprotection and Efficacy as First- line Immunosuppression Trial (BENEFIT) 008 study-Prinicipal Investigator-study completed
  • A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)- completed at our site
  • Biomarkers of acute kidney injury after cardiac surgery(TRIBE-AKI): A pilot study in collaboration with Yale University-USA– Prinicipal Investigator –Study ongoing.
  • Prospective, Multicentre, Randomised, Double-Blind, Parallel Group Study Comparing the Therapeutic Biosimilarity of Epostim™(GMX) with Eprex® (J & J) when given Intravenously to Patients undergoing Chronic Haemodialysis and on Maintenance Erythropoietin Treatment for Anemia Associated with End-Stage Renal Disease ( ESRD) Prinicipal Investigator - study ongoing
  • Belatacept Evaluation of Nephroprotection and Efficacy as First- line Immunosuppression Trial (BENEFIT) 008 study-extension phase till 5 years-Prinicipal Investigator-study started in april 2010.
  • A phase III, randomized, comparative, open label study of intravenous iron oligosaccharide (MonoFer®) administered by weekly infusions or repeated bolus injections in comparison with oral iron sulphate in subjects with non-dialysis dependent chronic kidney disease subjects with renal-related anaemia- Prinicipal Investigator -Study started in june 2010
  • study of gaps in metabolic acidosis to unmask metabolic alkalosis
  • prospective study of renal disease in Sjogren’s syndrome
  • comparison of creatinine clearance and serum cystatin as markers for estimation of renal function-study completed
  • clinical outcomes in lupus nephritis(data collection completed)
  • An evaluation of safety and efficacy of rHu Epo in treatment of anemia in patients with chronic kidney disease-A prospective open labeled multicenter study-coinvestigator(completed)
  • A randomized single blinded active drug comparitive parallel group, mulitcenter, multinational therapeutic confirmatory study to evaluate safety and efficacy of aropotin v/s espogen in chronic kidney disease patients-co investigator(completed)
  • A Randomized, Double-Blind, Placebo-Controlled, Four Arm, Parallel-Group, Multicenter, Multinational, Safety And Efficacy Trial of 100 mg, 300 mg and 900 mg of Abetimus Sodium In Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease”-Principal investigator-study completed
  • Belatacept Evaluation of Nephroprotection and Efficacy as First- line Immunosuppression Trial (BENEFIT) 008 study-Prinicipal Investigator-study completed
  • A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)- completed at our site
  • Biomarkers of acute kidney injury after cardiac surgery(TRIBE-AKI): A pilot study in collaboration with Yale University-USA– Prinicipal Investigator –Study ongoing.
  • Prospective, Multicentre, Randomised, Double-Blind, Parallel Group Study Comparing the Therapeutic Biosimilarity of Epostim™(GMX) with Eprex® (J & J) when given Intravenously to Patients undergoing Chronic Haemodialysis and on Maintenance Erythropoietin Treatment for Anemia Associated with End-Stage Renal Disease ( ESRD) Prinicipal Investigator - study ongoing
  • Belatacept Evaluation of Nephroprotection and Efficacy as First- line Immunosuppression Trial (BENEFIT) 008 study-extension phase till 5 years-Prinicipal Investigator-study started in april 2010.
  • A phase III, randomized, comparative, open label study of intravenous iron oligosaccharide (MonoFer®) administered by weekly infusions or repeated bolus injections in comparison with oral iron sulphate in subjects with non-dialysis dependent chronic kidney disease subjects with renal-related anaemia- Prinicipal Investigator -Study started in june 2010 
  • International Transplant Observership, Massachusetts General Hospital, Boston, USA, 2009
  • Roche Preceptorship Award, 2006 for Visiting Scholarship,University of Alabama, Birmingham, USA
  • International Society of Peritoneal Dialysis ISPD) Scholarship Award for training at The University of Missouri Health Sciences, Columbia, USA
  • International Society of Nephrology (ISN) Scholarship(2000)
  • Post Graduate Clinical Research Scholarship Award (1996)
  • Best Paper Award, Indian Society of Nephrology Conference(West zone chapter, November 1999)
  • First rank in Bombay university, DM (Nephrology)(August 1999) with honors
  • Third rank in All India entrance (DM) examinations for the fellowship courses (among a total of 350 candidates from all over the country), May 1997
  • Second rank in Bombay University, MD exams, July 1996 with distinction honors
  • First rank in Bombay university-Final MBBS examinations, April 1992
  • Patient and technique survival of diabetics on peritoneal dialysis: one-center’s experience and review of the literature. Clinical Nephrology, Vol. 69 – No3/2008(193-200)
  • Clinical outcomes of elderly patients undergoing chronic peritoneal dialysis: experiences from one center and a review of the literature: Int Urol Nephrol DOI 10.1007/s11255-007-9279-6
  • Diltiazem use in tacrolimus-treated renal transplant recipients. J Clin Pharm Ther 2004; 29:425-430
  • Volume expansion and sodium balance in peritoneal dialysis-part 1:recent concepts in pathogenesis Advances in peritoneal dialysis Vol 19 2003,36-43.
  • Volume expansion and sodium balance in peritoneal dialysis-part 2:newer insights in management Advances in peritoneal dialysis Vol 19 2003,44-52
  • Cost benefit analysis and prediction of 24 hour proteinuria from the spot protein-creatinine ratio –Clinical Nephrology, Vol 55-No 6/2001(436-447)
  • Acute renal failure in a renal donor due to primary antiphospholipid syndrome-Case report-American Journal of Nephrology 2001:21:55-57
  • Thrombocytopenia due to valproate in a renal transplant recepient-case report, Sounding board, 3-4Transplant Trends April 1999
  • Diffuse proliferative glomerulonephritis in a case of falciparum malaria; Case report; Journal of Renal Sciences, April 1999
  • 10.Hypokalemic periodic paralysis unmasks underlying Sjogren’syndrome- A case report ,and review of literature-IJEM Vol VII No 2 April 2005,97-99
  • Non diabetic renal disease in diabetes mellitus: a review-IJEM
  • An unusual case oh hypercalcemia with a multifactorial etiology-JPGM
  • Pathogenesis and medical management of renal stone disease-Journal of general medicine
  • International Society of Nephrology (ISN)
  • International Society of Peritoneal Dialysis (ISPD)
  • European Dialysis Transplant Association-European Renal Association (EDTA-ERA)
  • Indian Society of Nephrology
  • Indian Society of Nephrology-West Zone chapter
  • Joint Secretary-Zonal transplant coordination committee (ZTCC)
  • Indian Society of Organ transplantation (ISOT)
  • Association of Medical Consultants-Mumbai (AMC)
  • Peritoneal Dialysis Society of India (PDSI)
  • Infectious Disease Society of India (IDSI)
  • Mumbai Nephrology Group (MNG)